[11C]-DAA 1106 | 505084-32-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [11C]-DAA 1106
• 英文别名: Acetamide, N-(5-fluoro-2-phenoxyphenyl)-N-((2-methoxy-5-(methoxy-11C)phenyl)methyl)-；N-(5-fluoro-2-phenoxyphenyl)-N-[(5-methoxy-2-(111C)methoxyphenyl)methyl]acetamide
• CAS: 505084-32-2
• 化学式: C₂₃H₂₂FNO₄
• 分子量: 394.419
• InChiKey: DCRZYADKQRHHSF-KTXUZGJCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  48
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-(5-fluoro-2-phenoxyphenyl)-N-(2-hydroxy-5-methoxybenzyl)acetamide 以81的产率得到[11C]-DAA 1106
  参考文献：
  名称：

  Bioorganic & Medicinal Chemistry Letters 2003, 13, 201-204

  摘要：

  DOI：

文献信息

• ARYLOXYANILIDE IMAGING AGENTS
  申请人：Wadsworth Harry John

  公开号：US20120244073A1

  公开（公告）日：2012-09-27

  The present invention provides a novel radiolabeled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging. The in vivo imaging agent of the present invention demonstrates good selective binding to the peripheral benzodiazepine receptor (PBR), in combination with good brain uptake and in vivo kinetics following administration to a subject.

  本发明提供了一种新型放射性标记的芳氧基丙氨酸衍生物，适用于体内成像。与已知的芳氧基丙氨酸衍生物体内成像剂相比，本发明的体内成像剂具有更好的体内成像性能。本发明的体内成像剂在给予受试者后，表现出良好的选择性结合到周边苯二氮平受体（PBR），并具有良好的脑摄取和体内动力学。
• KIT FOR PRODUCING MOLECULAR PROBE FOR PET SCREENING FOR DRUG DISCOVERY
  申请人：Doi Hisashi

  公开号：US20110064662A1

  公开（公告）日：2011-03-17

  Disclosed is a kit for use in the production of a molecular probe for PET drug screening for the purpose of producing a compound containing a short-lived radionuclide for PET applications. Specifically disclosed is a kit comprising a compound represented by the formula (I), (II) or (III) or a salt thereof. In the formulae, X 1 , X 2 , X 3 , X 4 , X 5 and X 6 are as defined in the description.

  本发明揭示了一种用于制备PET药物筛选分子探针的试剂盒，其目的是为了生产含有短寿命放射性核素的化合物，以供PET应用。具体揭示的是一种试剂盒，包括公式（I），（II）或（III）或其盐所表示的化合物。在这些公式中，X1，X2，X3，X4，X5和X6如描述中所定义。
• DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT
  申请人：Lehmann Lutz

  公开号：US20110200535A1

  公开（公告）日：2011-08-18

  This invention relates to novel compounds suitable for labelling or already labelled by 18 F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for therapy and diagnostic imaging by positron emission tomography (PET).

  本发明涉及新的化合物，适用于标记或已被18F标记，制备这种化合物的方法，包含这种化合物的组合物，包含这种化合物或组合物的试剂盒，以及这种化合物、组合物或试剂盒在正电子发射断层扫描（PET）的治疗和诊断成像中的应用。
• PHENYLOXYANILINE DERIVATIVES
  申请人：LEHMANN Lutz

  公开号：US20110097269A1

  公开（公告）日：2011-04-28

  The present invention relates to phenyloxyaniline derivatives, to methods of their production and to uses thereof.

  本发明涉及苯氧基苯胺衍生物，其生产方法和用途。
• ARYLOXYANILIDE DERIVATIVES
  申请人：Wadsworth Harry John

  公开号：US20120003154A1

  公开（公告）日：2012-01-05

  The present invention provides a novel radiolabeled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging. The in vivo imaging agent of the present invention demonstrates good selective binding to the peripheral benzodiazepine receptor (PBR), in combination with good brain uptake and in vivo kinetics following administration to a subject.

  本发明提供了一种新型放射性标记的芳氧基脯氨酸衍生物，适用于体内成像。与已知的芳氧基脯氨酸衍生物体内成像剂相比，本发明的体内成像剂具有更好的体内成像性能。本发明的体内成像剂在给予受试者后，表现出良好的选择性结合外周苯二氮平受体（PBR），结合良好的脑吸收和体内动力学。